Starpharma Holdings Limited (ASX: SPL) shares edged lower despite the company achieving significant progress in its drug delivery portfolio across proprietary VivaGel® and DEP®. On Friday, 30 December 2018 SPL stock ended the week at $1.525, down 2.244%.
During 2018, the company posted successful results of clinical trial and attained international licenses. It has also submitted a New Drug Application (NDA) to the US FDA among other commercial milestones achieved during the period.
Starpharma’s Dendrimer platform technology was the highlight which enabled Starpharma to enhance the high versatile delivery platform for improving drugs performance. The strategic utilisation of this technology has served as the principal wheel in the development of novel therapies like VivaGel® products.
Monetizing and commercializing the products at the ideal stage remains at the heart of company’s strategy. It provides the optimization of product value without the need to carry the cost-burden of funding the complete development for all products at once.
The strategy underscores the company’s target to get the product licensed at optimal stage. This maximizes the value after which the company reinvests the proceeds into its product portfolio pipeline, especially high-potential DEP® drug.
Starpharma Chairman Robert Thompson stated that commercialization and regulatory activities have been the primary focus of the company over the past 12 months
VivaGel® BV, a proprietary dendrimer for bacterial vaginosis, has already been approved for marketing in Australia and the European Union. Currently, it is being reviewed by US FDA on fast track basis that may take not less than six months from acceptance.
Mr. Thompson stated that US FDA accepted the filing of NDA for VivaGel® BV in the first time without raising any issues. The confirmation outlines the completeness of the clinical and regulatory data packages.
Another proprietary product of the Starpharma includes DEP® cabazitaxel which delivered the results of complete tumour regression in Phase 1 trial and 100% survival of patients with Pancreatic cancer, which earlier had the one-year relative survival rate of 20%. This Starpharma’s DEP® cabazitaxel reportedly outperformed Jevtana® cabazitaxel in a human breast cancer model regarding safety, efficacy and survival. Currently, Starpharma’s internal product DEP® irinotecan is ramping up the preparation work to commence phase 1 of 2 trial in Fiscal 2019.
Starpharma’s Abraxane® has reportedly generated annual total sales of US$1.2 billion while Gemcitabine, before patent expiry, had a record sale of US$1.7 billion.
Notwithstanding these recent progress in Group’s drug delivery portfolio, the market got bearish for Starpharma’s stock, today. But we can see that the Starpharma Holdings Limited has caught the investors’ attention in the long run, as its share price has gone up 6.86% over the past one year and 24.80% over the last six months.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.